Clinical prospective study to investigate efficacy and safety of immune-cell therapy for malignant tumors
Not Applicable
Recruiting
- Conditions
- Malignant tumor
- Registration Number
- JPRN-UMIN000004610
- Lead Sponsor
- Kanazawa university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have: 1) T cell, NK cell lymphoma and leukemia 2) HTLV-I Ab and/or HIV Ab positive (LAK therapy), HIV Ab positive (DC therapy) 3) interstitial pneumonia, including their history or predisposition of them, 4) Active autoimmune diseases 5) Active cardiac disease 6) Serious drug allergy 7) Pregnancy woman, or woman with suspected pregnancy, lactating woman 8) Responsible doctors judged the patient inappropriate for the clinical study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival
- Secondary Outcome Measures
Name Time Method Progression free survival Relapse free survival Antitumor effect Quality of life Severe Adverse Event (SAE) Immunological response